1. Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
- Author
-
Juan Carlos López‐Azor, Lourdes Vicent, María Jesús Valero‐Masa, Alberto Esteban‐Fernández, Manuel Gómez‐Bueno, Ángel Pérez, Pablo Díez‐Villanueva, Javier De‐Juan, Ángel Manuel‐Iniesta, Ramón Bover, Susana delPrado, and Manuel Martínez‐Sellés
- Subjects
Heart failure ,Sacubitril/valsartan ,Reduced ejection fraction ,Hospitalization ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real‐life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non‐selected population, in the PIONEER‐HF trial, and in non‐selected outpatients. Methods and results Multicentre registry included 527 patients: 100 were started on sacubitril/valsartan during hospitalization (19.0%) and 427 as outpatients (81.0%). Compared with those in the pivotal trial, inpatients in our cohort were older (71 ± 12 vs. 61 ± 14 years; P
- Published
- 2019
- Full Text
- View/download PDF